Three COVID-19 resistant small caps to put in your portfolio
In times like these, you wonder if there are any stocks that can outperform in a market crisis. Here are three small caps that could potentially shine during this bear market.
The ship builder Austal (ASB) is a key source of diversification in the Under the Radar’s small cap portfolio since around 90% of revenue is contracted from US and Australian governments. We think companies will be able to rely on previously contracted revenue from government customers. Governments will be reluctant to allow their defence capabilities to diminish because of the impact of this virus.
There are big risks, but it helps if your operations are essential. Last month Austal announced that its US operations, employing 4000 people, are to remain operational, having been designated mission critical.
Then there is Freedom Foods (FNP). It’s not hard to see why consumers are looking for its combination of dairy and plant based food products, which include milk, nutritional powders, cereals, muesli bars and nuts. People need nutritious foods more than ever.
Under the Radar special trial offer
nabtrade customers get exclusive free access to Under the Radar Report's expert independent ASX Stock research and Share Portfolio Advice.
Last month, which seems like a millennium ago, the group said it’s experiencing “strong demand for key products” including UHT dairy and plant beverages and cereals and snacks. Further, the company said it would be able to continue to supply domestic and export markets; namely its retailer customer base. Its shares spiked over 20% on the news to as high as $5.10 but have come back on market-wide selling.
The problems in the food supply chain are in domestic groups importing products because they are having difficulty getting access to labelling and brand packaging. Freedom do not seem to have these issues, as far as we are aware.
What it does have is debt of almost $200 million and climbing, having spent well over $700m on a number of initiatives, including upgrading its UHT dairy processing plant in Shepparton. There is no disclosure of debt covenants, but based on similar companies we think Freedom has enough room to move.
The specialist pharmaceutical company Medical Developments (MVP) is on the riskier side compared to the other two, but is still a chance of achieving similar market penetration in non-opioid pain relief around the world that it has achieved in Australia, with its famed Green Whistle aka Penthrox.
Who doesn’t need a bit of pain relief right now?
Last month, which seems like a millennium ago, the group said it’s experiencing “strong demand for key products” including UHT dairy and plant beverages and cereals and snacks. Further, the company said it would be able to continue to supply domestic and export markets; namely its retailer customer base. Its shares spiked over 20% on the news to as high as $5.10 but have come back on market-wide selling.
The problems in the food supply chain are in domestic groups importing products because they are having difficulty getting access to labelling and brand packaging. Freedom do not seem to have these issues, as far as we are aware.
What it does have is debt of almost $200 million and climbing, having spent well over $700m on a number of initiatives, including upgrading its UHT dairy processing plant in Shepparton. There is no disclosure of debt covenants, but based on similar companies we think Freedom has enough room to move.
The specialist pharmaceutical company Medical Developments (MVP) is on the riskier side compared to the other two, but is still a chance of achieving similar market penetration in non-opioid pain relief around the world that it has achieved in Australia, with its famed Green Whistle aka Penthrox.
Who doesn’t need a bit of pain relief right now?
Last month, which seems like a millennium ago, the group said it’s experiencing “strong demand for key products” including UHT dairy and plant beverages and cereals and snacks. Further, the company said it would be able to continue to supply domestic and export markets; namely its retailer customer base. Its shares spiked over 20% on the news to as high as $5.10 but have come back on market-wide selling.
The problems in the food supply chain are in domestic groups importing products because they are having difficulty getting access to labelling and brand packaging. Freedom do not seem to have these issues, as far as we are aware.
What it does have is debt of almost $200 million and climbing, having spent well over $700m on a number of initiatives, including upgrading its UHT dairy processing plant in Shepparton. There is no disclosure of debt covenants, but based on similar companies we think Freedom has enough room to move.
The specialist pharmaceutical company Medical Developments (MVP) is on the riskier side compared to the other two, but is still a chance of achieving similar market penetration in non-opioid pain relief around the world that it has achieved in Australia, with its famed Green Whistle aka Penthrox.
Who doesn’t need a bit of pain relief right now?
Under the Radar special trial offer
nabtrade customers can access a 21-day trial offer to Under the Radar Report.
